Laronib 100mg Capsule (Larotrectinib)

Laronib 100mg Capsule (larotrectinib) is a prescription-based anticancer medicine. It is used to treat solid tumors in adult and pediatric patients with Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. It contains larotrectinib as an active ingredient, which belongs to a drug class known as tyrosine kinase inhibitor (TKI). It works by blocking the action of specific TRK proteins that regulate cancer cell growth. This can decrease cancer progression and cancer spread. Doctors advise undergoing molecular testing to confirm the presence of an NTRK gene fusion before treatment.

The capsule is taken orally and exactly as prescribed by the doctor. The capsule must be swallowed whole with water and should not be crushed, chewed, or broken. It is usually taken with or without food. Larotrectinib 100mg Capsule is given twice daily, and a doctor decides the dose and timings according to the patient's condition, combination therapy, clinical response, and stage of cancer. Patients are advised not to change the dosage because it can lead to severe side effects.

Common side effects include tiredness, nausea, dizziness, vomiting, constipation, diarrhea, and increased liver enzymes. A few patients can undergo severe side effects, including confusion, dizziness, memory or concentration problems, mood changes, and coordination difficulties. Most of the Larotrectinib 100mg Capsule side effects tend to resolve when the body adapts to the medicine. However, report to your doctor if you experience serious side effects.

Larotrectinib can interact with CYP3A enzymes; therefore, review it before the treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Larotrectinib 100mg Capsule must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Stomach cancers and adult and pediatric patients with solid tumors that have an NTRK gene fusion 

Side effects are undesirable symptoms that can result from any medical treatment. Like any other medicine, Laronib 100mg Capsule (Larotrectinib 100mg) also causes some adverse impact on the body, most of which resolve without any medical attention.

Some common side effects include:
● Anemia
● Fatigue
● Hypoalbuminemia
● Increased alkaline phosphatase
● Nausea
● Dizziness
● Vomiting
● Cough
● Constipation
● Neutropenia
● Diarrhea
● Pyrexia
● Peripheral edema
● Increased weight
● Headache
● Muscular weakness
● Decreased appetite
● Abdominal pain or back pain
However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.

Take the Laronib 100mg Capsule (larotrectinib) in the exact dose as prescribed by the doctor. The typical dose of this capsule varies with the age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results. It should be swallowed whole with water without crushing, chewing, or opening the capsule. Do not skip doses or take a double dose to make up for a missed one. 

● Drilon, A. E., DuBois, S. G., Farago, A. F., Geoerger, B., Grilley-Olson, J. E., Hong, D. S., ... & Doz, F. P. (2019). Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.
● Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., ... & Drilon, A. (2020). Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. The Lancet Oncology, 21(4), 531-540.
● Carlson, J. J., Italiano, A., Brose, M. S., Federman, N., Lassen, U., Kummar, S., & Sullivan, S. D. (2022). Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer. The American journal of managed care, 28(2 Suppl), S26.
● Scott, L. J. (2019). Larotrectinib: first global approval. Drugs, 79(2), 201-206.
● Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., ... & Hyman, D. M. (2018). Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. New England Journal of Medicine, 378(8), 731-739.